FOLD - Amicus Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
12.98
-0.18 (-1.33%)
As of 3:29PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close13.16
Open13.29
Bid12.99 x 2200
Ask13.00 x 2900
Day's Range12.86 - 13.48
52 Week Range12.15 - 17.62
Volume1,383,336
Avg. Volume1,990,707
Market Cap2.456B
Beta1.39
PE Ratio (TTM)N/A
EPS (TTM)-1.69
Earnings DateNov 6, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.83
Trade prices are not sourced from all markets
  • Lake Nona may get global biotech firm to build facility, create 300+ high-wage jobs
    American City Business Journals4 hours ago

    Lake Nona may get global biotech firm to build facility, create 300+ high-wage jobs

    Orlando City Council approved a nearly $380,000 incentive deal Aug. 20 for a global tech and biopharmaceutical firm to build a major manufacturing plant in Lake Nona. Cranbury, N.J.-based Amicus Therapeutics Inc. (Nasdaq: FOLD) wants to build a 190,690-square-foot facility — its first biologic drug substance manufacturing plant with associated research and development in Lake Nona. The company will create 316 jobs in Orlando by Dec. 31, 2024.

  • Benzinga8 days ago

    The Week Ahead: Nvidia, Retailer Earnings In Focus

    Below is a list of notable corporate events for the week beginning August 13. Note, this list is not comprehensive and all dates are subject to change. All times are ET. View more earnings on NTAP Monday ...

  • Amicus (FOLD) Gets FDA Nod for Fabry Disease Drug Galafold
    Zacks8 days ago

    Amicus (FOLD) Gets FDA Nod for Fabry Disease Drug Galafold

    Amicus (FOLD) gets a major boost with the FDA approval of lead candidate, Galafold (migalastat) 123 mg capsules for the treatment of Fabry disease.

  • Reuters8 days ago

    Amicus sets $315,000 price for new Fabry disease treatment

    Amicus Therapeutics on Monday set an average price of $315,000 per year for its newly approved Fabry disease treatment, a price it believes is below that of the main existing treatment in the United States. Galafold - approved on Friday by U.S. regulators - is the first new Fabry disease treatment in the country in over 15 years, and will compete with Sanofi SA's infused Fabrazyme, which has an average U.S. list price of $340,000 for adults, according to Amicus. Galafold is an oral therapy for Fabry disease, a sometimes fatal genetic condition in which accumulation of fat damages several organs.

  • Benzinga9 days ago

    The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

    The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) has experienced volatility amid the release of another spate of earnings reports.  Even as the earnings season winds down, the upcoming week ...

  • Reuters11 days ago

    Amicus Therapeutics receives U.S. approval for Fabry disease drug

    U.S. health regulators on Friday approved Amicus Therapeutics' Galafold, the first oral therapy to treat Fabry disease, a rare, sometimes fatal condition in which accumulation of fat damages several organs. Galafold, known chemically as migalastat, will be the first new Fabry treatment on the U.S. market in over 15 years, and will compete with Sanofi SA’s infused Fabrazyme. An estimated 3,000 people in the United States are diagnosed with the disease.

  • GlobeNewswire11 days ago

    FDA Approves Galafold™ (migalastat) for the Treatment of Certain Adult Patients with Fabry Disease

    Amicus Therapeutics (FOLD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Galafold™ (migalastat) 123 mg capsules. Galafold is an oral, precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data.

  • Amicus Therapeutics (FOLD) Reports Q2 Loss, Tops Revenue Estimates
    Zacks14 days ago

    Amicus Therapeutics (FOLD) Reports Q2 Loss, Tops Revenue Estimates

    Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 0.00% and 12.65%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press14 days ago

    Amicus Therapeutics: 2Q Earnings Snapshot

    The Cranbury, New Jersey-based company said it had a loss of 33 cents per share. The results met Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was ...

  • GlobeNewswire14 days ago

    Amicus Therapeutics Announces Second Quarter 2018 Financial Results and Corporate Updates

    2 Q18 Net Product Sales of $21.3 M Driven by Galafold ® Expansion. Company Increases FY18 Global Galafold Revenue Guidance to $80 M- $90 M. Pompe Clinical, Regulatory and Manufacturing Activities Continue ...

  • ACCESSWIRE14 days ago

    Amicus Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Amicus Therapeutics, Inc. (NASDAQ: FOLD ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 8:30:00 AM Eastern ...

  • Benzinga15 days ago

    Q2 Earnings Outlook For Amicus Therapeutics

    On Tuesday, Amicus Therapeutics (NASDAQ: FOLD ) will release its latest earnings report. Decipher the announcement with Benzinga's help. Earnings and Revenue Analysts are predicting Amicus Therapeutics ...

  • GlobeNewswire21 days ago

    Report: Developing Opportunities within Amicus Therapeutics, Interpace Diagnostics Group, The Progressive, State Street, Alphabet, and VBI Vaccines — Future Expectations, Projections Moving into 2018

    NEW YORK, July 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amicus ...

  • GlobeNewswire21 days ago

    Amicus Therapeutics to Announce Second Quarter 2018 Financial Results on August 7, 2018

    CRANBURY, N.J., July 31, 2018-- Amicus Therapeutics today announced that the Company will host a conference call and live audio webcast on Tuesday, August 7, 2018 at 8:30 a.m. ET to discuss financial results ...

  • GlobeNewswire22 days ago

    Research Report Identifies General Dynamics, General Motors, Amicus Therapeutics, Drive Shack, Zoe's Kitchen, and Vishay Intertechnology with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, NY, July 30, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders ...

  • ACCESSWIRE22 days ago

    Stock Performance Review on Amicus Therapeutics and Three Other Biotech Stocks

    Stock Research Monitor: HEB, HTBX, and PBYI LONDON, UK / ACCESSWIRE / July 30, 2018/ If you want a free Stock Review on FOLD sign up now at www.wallstequities.com/registration . On Friday, benchmark US ...

  • Why Protalix Expanded Partnership with Chiesi
    Market Realist27 days ago

    Why Protalix Expanded Partnership with Chiesi

    On July 24, Protalix BioTherapeutics (PLX) expanded its partnership with Chiesi Farmaceutici. The expansion of the agreement allows Chiesi Farmaceutici exclusive US license for the development and commercialization of PRX-102 (pegunigalsidase alfa), which is Protalix’s modified version of the recombinant alpha-galactosidase-A protein. In October 2017, Protalix and Cheisi entered an exclusive partnership for the development and commercialization of PRX-102 outside the US for the treatment of individuals with Fabry disease.

  • ACCESSWIRE2 months ago

    Free Pre-Market Technical Recap on Sarepta Therapeutics and Three Additional Biotech Stocks

    LONDON, UK / ACCESSWIRE / June 29, 2018 / If you want a free Stock Review on SRPT sign up now at www.wallstequities.com/registration. On Thursday, June 28, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Thursday's trading session in bullish territories.

  • All You Need To Know About Amicus Therapeutics Inc’s (NASDAQ:FOLD) Financial Health
    Simply Wall St.2 months ago

    All You Need To Know About Amicus Therapeutics Inc’s (NASDAQ:FOLD) Financial Health

    Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Amicus Therapeutics Inc (NASDAQ:FOLD), with a market capitalization of US$2.89b, rarely draw their attention from the investingRead More...

  • Benzinga2 months ago

    Benzinga's Daily Biotech Pulse: Pain Therapeutics Drops 70%, Neon To Begin Trading

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 26) AngioDynamics, Inc. (NASDAQ: ANGO ) Chembio Diagnostics Inc ...

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Amicus Therapeutics and Sage Therapeutics

    NEW YORK, NY / ACCESSWIRE / June 27, 2018 / U.S. markets rebounded on Tuesday after experiencing steep losses the past week due to growing trade tensions. The Dow Jones Industrial Average increased 0.12 ...

  • GlobeNewswire2 months ago

    Amicus Therapeutics Announces European Regulatory and Clinical Updates for AT-GAA in Pompe Disease

    Amicus Therapeutics (FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, announced today regulatory and clinical advancements in its development program for AT-GAA for Pompe disease following guidance from regulators in the European Union as well as guidance on manufacturing and bio-comparability from German regulatory authorities (BfArM). 2) to discuss whether Amicus may pursue a pathway for AT-GAA that includes a conditional marketing approval (CMA) application in Europe.  Amicus has concluded this series of interactions and has now received written guidance from the SAWP.

  • GlobeNewswire2 months ago

    Amicus Therapeutics Appoints President and COO Bradley L. Campbell to Board of Directors

    Amicus Therapeutics (FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced the election and appointment of  the Company’s President and Chief Operating Officer Bradley L. Campbell to its Board of Directors, effective immediately. John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, “On behalf of our Board of Directors, I am pleased to announce Bradley’s appointment to the Board.

  • GlobeNewswire3 months ago

    Amicus Therapeutics to Present at Goldman Sachs 39th Annual Global Healthcare Conference

    CRANBURY, N.J., June 01, 2018-- Amicus Therapeutics, Inc. announced today that John F. Crowley, Chairman and Chief Executive Officer, will participate in a corporate overview and fireside chat at the upcoming ...

  • GlobeNewswire3 months ago

    Amicus Therapeutics Launches Galafold® (Migalastat) for Fabry Disease in Japan

    Amicus Therapeutics (FOLD) has initiated the commercial launch of the oral small molecule pharmacological chaperone Galafold® capsules 123mg (migalastat) for treatment of patients aged 16 years and older with a confirmed diagnosis of Fabry disease (alpha-galactosidase A deficiency) and who have an amenable mutation. Galafold is the first and only oral precision medicine for Fabry disease in Japan. John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, “The launch of Galafold in Japan, less than one year after our J-NDA submission, provides a significant opportunity for us to deliver this oral and differentiated precision medicine to amenable Fabry patients living in Japan.